Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by Mount Sinai School of Medicine
Sponsor:
Collaborators:
Rare Diseases Clinical Research Network
Information provided by (Responsible Party):
Mount Sinai School of Medicine
ClinicalTrials.gov Identifier:
NCT01688895
First received: September 14, 2012
Last updated: August 25, 2014
Last verified: August 2014
  Purpose

The initial objective of this protocol is to assemble a well-documented group of patients with confirmed diagnoses of the erythropoietic protoporphyrias, including autosomal recessive Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP) for clinical, biochemical, and genetic studies. The long-term objectives are (1) to conduct a longitudinal investigation of the natural history, complications, and therapeutic outcomes in people with erythropoietic protoporphyria, (2) to systematically investigate the psychological effects of the erythropoietic protoporphyrias on children and adults, and (3) to investigate the correlation between the identified genotypes and the resulting clinical presentation, also determining the possible interaction of other genetic markers.


Condition
Erythropoietic Protoporphyria
EPP
X-Linked Protoporphyria
XLP
XLPP
X-Linked Dominant Erythropoietic Protoporphyria
XLEPP
XLDP

Study Type: Observational
Study Design: Observational Model: Cohort
Official Title: Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact

Resource links provided by NLM:


Further study details as provided by Mount Sinai School of Medicine:

Primary Outcome Measures:
  • Clinical Analysis [ Time Frame: baseline, then annually, up to 3 years ] [ Designated as safety issue: No ]
    To develop disease severity scores to describe the combined frequency and severity of disease manifestations, utilizing linear mixed effects models & stratification by age of onset.


Secondary Outcome Measures:
  • Laboratory Analysis [ Time Frame: baseline, then annually, up to 3 years ] [ Designated as safety issue: No ]
    To evaluate porphyrin and porphyrin precursor levels alone or by genotype and porphyria subtype

  • Relationship between disease severity and biomarkers [ Time Frame: baseline, then annually, up to 3 years ] [ Designated as safety issue: No ]
    To develop longitudinal models that relate, for example, porphyrin and porphyrin precursor levels alone or in concert with age, genotype and other features to the disease manifestation frequency.


Biospecimen Retention:   Samples With DNA

DNA extracted from peripheral blood sample or buccal (inside cheek) sampling for DNA analysis; whole blood in ACD anti-coagulant to establish a lymphoid cell line, red blood cells and plasma for biochemical assays.


Estimated Enrollment: 150
Study Start Date: July 2012
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: September 2019 (Final data collection date for primary outcome measure)
Groups/Cohorts
Erythropoietic Protoporphyria (EPP)
Individuals with a documented diagnosis of EPP
X-Linked Protoporphyria (XLP)
Individuals with a documented diagnosis of XLP
Erythropoietic protoporphyria, unspecified
Individuals with clinical and/or biochemical diagnosis of an erythropoietic protoporphyria, but the specific type (EPP or XLP) has not been determined

Detailed Description:

The porphyrias are a group of rare metabolic diseases that may present in childhood or adult life and are due to deficiencies of enzymes in the heme biosynthetic pathway. The most common manifestations are related to accumulation of intermediates in the pathway and usually occur as acute neurological attacks (as in the acute or hepatic porphyrias), or cutaneous photosensitivity (as in the cutaneous porphyrias, including the erythropoietic protoporphyrias). Multiple mutations have been identified in each of the porphyrias [Anderson, 2001]. The risk of disability or death from these disorders is significant, in part because diagnosis is often delayed due to lack of adoption of diagnostic testing in clinical practice. Moreover, the natural history of these disorders is not well described and it is not known what determines differences in outcomes. New therapies are needed. For existing therapies, high-quality evidence on short and long term efficacy and safety is generally lacking [Sood 2008]. Therefore, the purpose of this study of a large group of patients with EPP and XLP is to provide a better understanding of the natural history of these disorders, as affected by available therapies, and to aid in developing new forms of treatment. Much of the data collected on subjects as participants in the Longitudinal Study of the Porphyrias will be accessed for this study specific to the investigation of the erythropoietic protoporphyrias. To maximize the information that can be informative in our objectives, additional data will be collected, including additional biochemical findings and EPP-specific psychosocial parameters.

The Office of Rare Diseases (ORD) of the National Institutes of Health (NIH) established a Rare Diseases Clinical Research Network (RDCRN) in collaboration with other NIH Institutes and currently has funded 19 rare diseases clinical research consortia and one Data Management and Coordinating Center. The Porphyrias Consortium was created as part of the RDCRN, to study the human porphyrias. The Porphyrias Consortium is a consortium of the academic institutions listed in the participating institutions table. All Centers in the Porphyrias Consortium are participating in this study. Additional centers may be added if funding is available.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Subjects will be recruited from the following resources:

  1. Patients followed by one of the Investigators
  2. The American Porphyria Foundation (APF)
  3. The Rare Diseases Clinical Research Network (RDCRN) Contact Registry
  4. Non-study Physician referrals
  5. Self-referrals, including family members of individuals diagnosed with Porphyria (proband) and other individuals who may have heard about the study from other subjects or prospective subjects.
  6. Medical Records Review
Criteria

Inclusion Criteria:

All subjects must also be enrolled in the Longitudinal Study of the Porphyrias.

Diagnostic criteria: #1 (a) AND [#2 (a and/or b) OR #3 (a or b or c)]

  • Clinical features - a or b required

    1. A history of nonblistering cutaneous photosensitivity.
    2. A diagnosis of EPP or XLP in a relative.
  • Biochemical findings ('a' is required)

    1. A marked increase in erythrocyte protoporphyrin [total erythrocyte protoporphyrin >200 ug/dL, or more than 1.5-fold increase (relative to ULN of 80 ug/dL)], with a predominance of free protoporphyrin (85-100% in EPP and 50-85% in XLP). Note: Methods in some laboratories for measuring free erythrocyte protoporphyrin (FEP) actually measure zinc protoporphyrin, so cannot be relied upon for diagnosis or characterizing the phenotype in EPP and XLP.
    2. Increased plasma porphyrins in almost all cases and a fluorescence emission peak at ~634 nm.
    3. Normal urinary porphyrins (except in patients with hepatobiliary impairment), and normal ALA and PBG.
  • Molecular findings - one of the following:

    1. A disease causing FECH mutation trans to the IVS3-48C>T low expression FECH allele
    2. Two disease-causing FECH mutations
    3. A gain-of-function ALAS-2 C-terminal deletion/exon 11 mutation (in XLP).

Others who may be enrolled

  • Relatives who may be asymptomatic but may share genetic traits, including disease-causing mutations, as demonstrated by DNA studies in an index case.
  • Possible but unconfirmed cases that meet some but not all diagnostic criteria for a definite diagnosis; these are likely to be informative as a comparison group.

Exclusion Criteria:

  • cases with elevations of porphyrins in urine, plasma or erythrocytes due to other diseases (i.e. secondary porphyrinuria or porphyrinemia), such as liver and bone marrow diseases [Gibson 2000].
  • patients with a prior diagnosis of porphyria that cannot be documented by review of existing medical records or repeat biochemical or DNA testing.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01688895

Contacts
Contact: Hetanshi Naik, MS, CGC 212-659-7699 hetanshi.naik@mssm.edu
Contact: Manisha Balwani, MD 212-241-8384 manisha.balwani@mssm.edu

Locations
United States, Alabama
University of Alabama, Birmingham Recruiting
Birmingham, Alabama, United States, 35294-0005
Contact: Joseph R Bloomer, MD    205-996-9543    jbloomer@uab.edu   
Contact: Toni Seay, BS    205-934-7332    tamartin@uab.edu   
Principal Investigator: Joseph R Bloomer, MD         
United States, California
University of California, San Francisco Recruiting
San Francisco, California, United States, 94143
Contact: D. Montgomery Bissell, MD    415-476-8405    montgomery.bissell@ucsf.edu   
Contact: Sam Zenhari    415-476-8405    Sam.ZenhariAbharrodi@ucsf.edu   
Principal Investigator: D. Montgomery Bissell, MD         
United States, New York
Icahn School of Medicine at Mount Sinai Recruiting
New York, New York, United States, 10029
Principal Investigator: Manisha Balwani, MD         
United States, North Carolina
Carolinas Medical Center and HealthCare System Recruiting
Charlotte, North Carolina, United States, 28203
Contact: Herbert L Bonkovsky, MD    704-355-9645    Herbert.Bonkovsky@carolinashealthcare.org   
Contact: Gale Groseclose, RN    704-355-4875    Gale.Grosclose@carolinashealthcare.org   
Principal Investigator: Herbert L Bonkovsky, MD         
United States, Texas
University of Texas Medical Branch Recruiting
Galveston, Texas, United States, 77555
Contact: Karl E Anderson, MD    409-772-4661    kanderso@utmb.edu   
Contact: Csilla Hallberg, MD    409-772-6287    challberg@utmb.edu   
Principal Investigator: Karl E Anderson, MD         
United States, Utah
University of Utah Recruiting
Salt Lake City, Utah, United States, 84132
Contact: John Phillips, PhD    801-585-3229    john.phillips@hsc.utah.edu   
Contact: Tiffanie Hales    801-213-3367    tiffanie.hales@hsc.utah.edu   
Principal Investigator: John Phillips, PhD         
Sponsors and Collaborators
Mount Sinai School of Medicine
Rare Diseases Clinical Research Network
Investigators
Principal Investigator: Manisha Balwani, MD Mount Sinai School of Medicine
  More Information

Additional Information:
No publications provided

Responsible Party: Mount Sinai School of Medicine
ClinicalTrials.gov Identifier: NCT01688895     History of Changes
Other Study ID Numbers: GCO 08-0959-04, HSM12-00307, U54DK083909
Study First Received: September 14, 2012
Last Updated: August 25, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Mount Sinai School of Medicine:
erythropoietic
protoporphyria
cutaneous
porphyria

Additional relevant MeSH terms:
Porphyrias
Porphyrias, Hepatic
Protoporphyria, Erythropoietic
Digestive System Diseases
Genetic Diseases, Inborn
Liver Diseases
Metabolic Diseases
Metabolism, Inborn Errors
Skin Diseases
Skin Diseases, Genetic
Skin Diseases, Metabolic

ClinicalTrials.gov processed this record on November 25, 2014